- Home
- MTLS vs ITOS Comparison
MTLS vs ITOS Comparison
Compare MTLS & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- ITOS
- Stock Information
- Founded
- MTLS 1990
- ITOS 2011
- Country
- MTLS Belgium
- ITOS United States
- Employees
- MTLS N/A
- ITOS N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTLS Technology
- ITOS Health Care
- Exchange
- MTLS Nasdaq
- ITOS Nasdaq
- Market Cap
- MTLS N/A
- ITOS 270.7M
- IPO Year
- MTLS 2014
- ITOS 2020
- Fundamental
- Price
- MTLS $5.51
- ITOS $6.70
- Analyst Decision
- MTLS
- ITOS Strong Buy
- Analyst Count
- MTLS 0
- ITOS 3
- Target Price
- MTLS N/A
- ITOS $25.67
- AVG Volume (30 Days)
- MTLS 131.3K
- ITOS 553.7K
- Earning Date
- MTLS 04-24-2025
- ITOS 04-28-2025
- Dividend Yield
- MTLS N/A
- ITOS N/A
- EPS Growth
- MTLS 43.31
- ITOS N/A
- EPS
- MTLS 0.17
- ITOS N/A
- Revenue
- MTLS $291,295,936.00
- ITOS $35,000,000.00
- Revenue This Year
- MTLS $6.55
- ITOS N/A
- Revenue Next Year
- MTLS $9.21
- ITOS $31.74
- P/E Ratio
- MTLS $30.75
- ITOS N/A
- Revenue Growth
- MTLS 6.16
- ITOS 177.89
- 52 Week Low
- MTLS $3.93
- ITOS $4.80
- 52 Week High
- MTLS $9.69
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- MTLS 63.19
- ITOS 49.45
- Support Level
- MTLS $5.21
- ITOS $6.58
- Resistance Level
- MTLS $5.43
- ITOS $7.80
- Average True Range (ATR)
- MTLS 0.20
- ITOS 0.51
- MACD
- MTLS 0.09
- ITOS -0.03
- Stochastic Oscillator
- MTLS 93.39
- ITOS 32.10
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.